Skip to main content
. 2020 Jun 24;28:7–15. doi: 10.1016/j.jare.2020.06.006

Fig. 5.

Fig. 5

Targeting the LncRNA ZFAS1 and EPAS1 in vitro and in vivo. (A) The mRNA levels of LncRNA ZFAS1 (left panel) and EPAS1 (right panel) GCA-H008 cells after knocking-down with siRNA were determined by RT-qPCR (n = 3). (B) Wound healing assay with knocking down LncRNA ZFAS1, EPAS1, or them together in GCA-H008 cells (n = 3). (C) Cell invasion assay with knocking down LncRNA ZFAS1, EPAS1, or them together in GCA-H008 cells (n = 3). (D) The cell proliferation analysis with knocking down LncRNA ZFAS1, EPAS1, or them together in GCA-H008 cells (n = 3). (E) Knocking down LncRNA ZFAS1, EPAS1, or them together decreased the tumor size in vivo (n = 12 for each group). *P < 0.05. (F) Representative figures for tumors isolated from the xenograft mice model of GCA established by subcutaneously injection of GCA-H008 cells (n = 6 for each group). GCA-H008: fresh isolated GCA cell line with high level of LncRNA ZFAS1; NC: negative control; *P < 0.05. The unpaired Student’s t test was used for two groups comparison and one-way ANOVA was used for multiple groups comparison.